$EBS insider trading
Over the last 12 months, Emergent BioSolutions insiders reported no purchases and 14 sales totaling $2.4M across SEC Form 4 filings. 64% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.4M 14 events
- Events · 12m
- 14 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 64% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Williams Paul AnthonySVP, Products Business · O | ▼ Sale | 3,000 | $8.4 | $25K | -1.9% | plan |
| May 1, 2026 | Zoon Kathryn CD | ▼ Sale | 17,202 | $8.4 | $144K | -17.7% | plan · 2 tranches |
| May 1, 2026 | DeGolyer Donald WD | ▼ Sale | 15,481 | $8.4 | $130K | -10.7% | plan · 2 tranches |
| May 1, 2026 | Dayal Sujata TyagiD | ▼ Sale | 13,761 | $8.4 | $116K | -12% | plan · 2 tranches |
| Apr 30, 2026 | Katkin KeithD | ▼ Sale | 15,481 | $8.28 | $128K | -13.9% | plan |
| Apr 1, 2026 | Williams Paul AnthonySVP, Products Business · O | ▼ Sale | 4,000 | $8.44 | $34K | -6% | plan |
| Feb 6, 2026 | Hartzel WilliamSVP, Bioservices · O | ▽ Sale to issuer | 5,771 | $10.92 | $63K | -5.6% | — |
| Feb 6, 2026 | Williams Paul AnthonySVP, Products Business · O | ▽ Sale to issuer | 8,655 | $10.92 | $95K | -10.1% | — |
| Feb 6, 2026 | Glessner ColeenEVP, Quality & Ethics, and CPL · O | ▽ Sale to issuer | 28,847 | $10.92 | $315K | -20% | — |
| Feb 6, 2026 | LINDAHL RICHARD SEVP, Chief Financial Officer · O | ▽ Sale to issuer | 46,155 | $10.92 | $504K | -15.8% | — |
| Dec 5, 2025 | Richard RonaldD | ▼ Sale | 21,984 | $11.97 | $263K | -18.3% | 2 tranches |
| Nov 10, 2025 | DeGolyer Donald WD | ▼ Sale | 17,801 | $10.54 | $188K | -12.9% | plan |
| Nov 7, 2025 | Dayal Sujata TyagiD | ▼ Sale | 8,552 | $10 | $86K | -8.8% | plan |
| Oct 7, 2025 | Glessner ColeenEVP, Quality & Ethics, and CPL · O | ▼ Sale | 30,608 | $10 | $306K | -17.5% | plan · late |
| Aug 15, 2025 | Zoon Kathryn CD | ▼ Sale | 7,086 | $8.87 | $63K | -9% | plan |
| Aug 12, 2025 | DeGolyer Donald WD | ▼ Sale | 7,844 | $8.65 | $68K | -5.4% | — |
Every $EBS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Emergent BioSolutions filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $EBS feed.